Is 68Ga–Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma?

Is 68Ga–Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma?:

We present the case of a 75-year-old man with osteosarcoma of the sternum in whom 68Ga-prostate-specific membrane antigen (PSMA) PET/CT showed high radiotracer activity in the primary tumor and metastatic lesions than 18F-FDG PET/CT. The present case shows that 68Ga-PSMA PET/CT is very useful for staging of osteosarcoma due to in vivo expression of PSMA. 68Ga-PSMA PET/CT can have potential effects on prognosis and in response assessment following treatment in osteosarcoma. The use of PSMA-targeted radioligand treatments may be beneficial especially in metastatic chemorefractory osteosarcoma. Received for publication July 17, 2020; revision accepted August 23, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Cihan Gündoğan, MD, Department of Nuclear Medicine, Gazi Yaşargil Training and Research Hospital, University of Health Sciences, Talaytepe, Üçkuyular Mahallesi Elaziğ Yolu, Üzeri 10.Km, 21010 Kayapinar/Diyarbakir, Turkey. E-mail: cihangd@hotmail.com. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.